Intervention Review

You have free access to this content

Betamimetics for inhibiting preterm labour

  1. James P Neilson1,*,
  2. Helen M West2,
  3. Therese Dowswell2

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 5 FEB 2014

Assessed as up-to-date: 31 DEC 2013

DOI: 10.1002/14651858.CD004352.pub3


How to Cite

Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD004352. DOI: 10.1002/14651858.CD004352.pub3.

Author Information

  1. 1

    The University of Liverpool, Department of Women's and Children's Health, Liverpool, UK

  2. 2

    The University of Liverpool, Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health, Liverpool, UK

*James P Neilson, Department of Women's and Children's Health, The University of Liverpool, First Floor, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool, L8 7SS, UK. jneilson@liverpool.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 5 FEB 2014

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Funnel plot of comparison: 1 All betamimetics versus placebo, outcome: 1.1 Birth within 48 hours of treatment.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 All betamimetics versus placebo, outcome: 1.2 Perinatal death (7 days).
[Analysis 1.1]
Analysis 1.1. Comparison 1 All betamimetics versus placebo, Outcome 1 Birth within 48 hours of treatment.
[Analysis 1.2]
Analysis 1.2. Comparison 1 All betamimetics versus placebo, Outcome 2 Perinatal death (7 days).
[Analysis 1.3]
Analysis 1.3. Comparison 1 All betamimetics versus placebo, Outcome 3 Respiratory distress syndrome.
[Analysis 1.4]
Analysis 1.4. Comparison 1 All betamimetics versus placebo, Outcome 4 Cerebral palsy.
[Analysis 1.5]
Analysis 1.5. Comparison 1 All betamimetics versus placebo, Outcome 5 Birth within 7 days.
[Analysis 1.6]
Analysis 1.6. Comparison 1 All betamimetics versus placebo, Outcome 6 Birth less than 37 weeks' gestation.
[Analysis 1.7]
Analysis 1.7. Comparison 1 All betamimetics versus placebo, Outcome 7 Maternal death.
[Analysis 1.8]
Analysis 1.8. Comparison 1 All betamimetics versus placebo, Outcome 8 Pulmonary oedema.
[Analysis 1.9]
Analysis 1.9. Comparison 1 All betamimetics versus placebo, Outcome 9 Cardiac arrhythmias.
[Analysis 1.10]
Analysis 1.10. Comparison 1 All betamimetics versus placebo, Outcome 10 Myocardial ischemia.
[Analysis 1.11]
Analysis 1.11. Comparison 1 All betamimetics versus placebo, Outcome 11 Hypotension.
[Analysis 1.12]
Analysis 1.12. Comparison 1 All betamimetics versus placebo, Outcome 12 Cessation of treatment due to adverse drug reaction.
[Analysis 1.13]
Analysis 1.13. Comparison 1 All betamimetics versus placebo, Outcome 13 Palpitation.
[Analysis 1.14]
Analysis 1.14. Comparison 1 All betamimetics versus placebo, Outcome 14 Tachycardia.
[Analysis 1.15]
Analysis 1.15. Comparison 1 All betamimetics versus placebo, Outcome 15 Chest pain.
[Analysis 1.16]
Analysis 1.16. Comparison 1 All betamimetics versus placebo, Outcome 16 Dyspnoea.
[Analysis 1.17]
Analysis 1.17. Comparison 1 All betamimetics versus placebo, Outcome 17 Tremor.
[Analysis 1.18]
Analysis 1.18. Comparison 1 All betamimetics versus placebo, Outcome 18 Hyperglycaemia.
[Analysis 1.19]
Analysis 1.19. Comparison 1 All betamimetics versus placebo, Outcome 19 Hypokalaemia.
[Analysis 1.20]
Analysis 1.20. Comparison 1 All betamimetics versus placebo, Outcome 20 Nausea or vomiting.
[Analysis 1.21]
Analysis 1.21. Comparison 1 All betamimetics versus placebo, Outcome 21 Nasal stuffiness.
[Analysis 1.22]
Analysis 1.22. Comparison 1 All betamimetics versus placebo, Outcome 22 Headaches.
[Analysis 1.23]
Analysis 1.23. Comparison 1 All betamimetics versus placebo, Outcome 23 Neonatal death.
[Analysis 1.24]
Analysis 1.24. Comparison 1 All betamimetics versus placebo, Outcome 24 Infant death.
[Analysis 1.25]
Analysis 1.25. Comparison 1 All betamimetics versus placebo, Outcome 25 Necrotising enterocolitis.
[Analysis 1.26]
Analysis 1.26. Comparison 1 All betamimetics versus placebo, Outcome 26 Sepsis or infection.
[Analysis 1.27]
Analysis 1.27. Comparison 1 All betamimetics versus placebo, Outcome 27 Fetal hypoglycaemia.
[Analysis 1.28]
Analysis 1.28. Comparison 1 All betamimetics versus placebo, Outcome 28 Fetal tachycardia.
[Analysis 1.29]
Analysis 1.29. Comparison 1 All betamimetics versus placebo, Outcome 29 Infant long-term neurological development (Bayley score: Psychomotor development).
[Analysis 1.30]
Analysis 1.30. Comparison 1 All betamimetics versus placebo, Outcome 30 Infant long-term neurological development (Bayley score: Mental development).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Terbutaline versus ritodrine, Outcome 1 Birth within 48 hours.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Terbutaline versus ritodrine, Outcome 2 Perinatal death.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Terbutaline versus ritodrine, Outcome 3 Respiratory distress syndrome.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Terbutaline versus ritodrine, Outcome 4 Birth within 7 days.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Terbutaline versus ritodrine, Outcome 5 Birth less than 28 weeks' gestation.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Terbutaline versus ritodrine, Outcome 6 Cessation of treatment due to adverse drug reactions.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Terbutaline versus ritodrine, Outcome 7 Any maternal adverse effects.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Terbutaline versus ritodrine, Outcome 8 Chest pain.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Terbutaline versus ritodrine, Outcome 9 Shortness of breath or dyspnea.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Terbutaline versus ritodrine, Outcome 10 Hyperglycaemia or abnormal glucose tolerance test.
[Analysis 2.11]
Analysis 2.11. Comparison 2 Terbutaline versus ritodrine, Outcome 11 Palpitations.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Terbutaline versus ritodrine, Outcome 12 Tachycardia.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Terbutaline versus ritodrine, Outcome 13 Arrhythmia.
[Analysis 2.14]
Analysis 2.14. Comparison 2 Terbutaline versus ritodrine, Outcome 14 Hypotension.
[Analysis 2.15]
Analysis 2.15. Comparison 2 Terbutaline versus ritodrine, Outcome 15 Nausea or vomiting.
[Analysis 2.16]
Analysis 2.16. Comparison 2 Terbutaline versus ritodrine, Outcome 16 Headache.
[Analysis 2.17]
Analysis 2.17. Comparison 2 Terbutaline versus ritodrine, Outcome 17 Anxiety.
[Analysis 2.18]
Analysis 2.18. Comparison 2 Terbutaline versus ritodrine, Outcome 18 Necrotising enterocolitis.
[Analysis 2.19]
Analysis 2.19. Comparison 2 Terbutaline versus ritodrine, Outcome 19 Neonatal death.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Fenoterol versus ritodrine, Outcome 1 Perinatal death.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Fenoterol versus ritodrine, Outcome 2 Respiratory distress syndrome.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Fenoterol versus ritodrine, Outcome 3 Tachycardia.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Fenoterol versus ritodrine, Outcome 4 Hypoglycaemia.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Fenoterol versus ritodrine, Outcome 5 Fetal bradycardia.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Fenoterol versus ritodrine, Outcome 6 Neonatal death.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 1 Birth within 48 hours.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 2 Respiratory distress syndrome.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 3 Periventricular haemorrhage grade 3-4.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 4 Birth less than 34 weeks.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 5 Birth less than 37 weeks.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 6 Any maternal adverse effects.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 7 Palpitations.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 8 Tachycardia.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 9 Nausea or vomiting.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 10 Headache.
[Analysis 4.11]
Analysis 4.11. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 11 Sepsis.
[Analysis 4.12]
Analysis 4.12. Comparison 4 Ritodrine loading dose versus incremental dose, Outcome 12 Neonatal death.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Hexoprenaline versus ritodrine, Outcome 1 Cessation of treatment due to adverse drug reactions.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Hexoprenaline versus ritodrine, Outcome 2 Any maternal adverse effects.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Hexoprenaline versus ritodrine, Outcome 3 Palpitations.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Hexoprenaline versus ritodrine, Outcome 4 Hypotension.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Hexoprenaline versus ritodrine, Outcome 5 Nausea or vomiting.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Hexoprenaline versus ritodrine, Outcome 6 Increase in fetal heart rate.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Hexoprenaline versus salbutamol, Outcome 1 Respiratory distress syndrome.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Hexoprenaline versus salbutamol, Outcome 2 Cessation of treatment due to adverse drug reactions.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Hexoprenaline versus salbutamol, Outcome 3 Any maternal adverse effects.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Hexoprenaline versus salbutamol, Outcome 4 Tachycardia.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Hexoprenaline versus salbutamol, Outcome 5 Nausea or vomiting.
[Analysis 6.6]
Analysis 6.6. Comparison 6 Hexoprenaline versus salbutamol, Outcome 6 Headache.
[Analysis 6.7]
Analysis 6.7. Comparison 6 Hexoprenaline versus salbutamol, Outcome 7 Tremor.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Terbutaline versus salbutamol, Outcome 1 BIrth within 48 hours.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Terbutaline versus salbutamol, Outcome 2 Side effects (overall).
[Analysis 7.3]
Analysis 7.3. Comparison 7 Terbutaline versus salbutamol, Outcome 3 Tachycardia.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Terbutaline versus salbutamol, Outcome 4 Dyspnea.
[Analysis 7.5]
Analysis 7.5. Comparison 7 Terbutaline versus salbutamol, Outcome 5 Nausea.
[Analysis 7.6]
Analysis 7.6. Comparison 7 Terbutaline versus salbutamol, Outcome 6 Anxiety.
[Analysis 7.7]
Analysis 7.7. Comparison 7 Terbutaline versus salbutamol, Outcome 7 Chills.
[Analysis 7.8]
Analysis 7.8. Comparison 7 Terbutaline versus salbutamol, Outcome 8 Oedema.
[Analysis 7.9]
Analysis 7.9. Comparison 7 Terbutaline versus salbutamol, Outcome 9 Duration of hospital admission (days).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Slow release versus normal release salbutamol, Outcome 1 Preterm birth (before 37 weeks).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Slow release versus normal release salbutamol, Outcome 2 Caesarean section.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Slow release versus normal release salbutamol, Outcome 3 Side effects leading to discontinuation of treatment.
[Analysis 8.4]
Analysis 8.4. Comparison 8 Slow release versus normal release salbutamol, Outcome 4 Nausea.
[Analysis 8.5]
Analysis 8.5. Comparison 8 Slow release versus normal release salbutamol, Outcome 5 Apgar score less than 7 at 5 minutes.